Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and vascular dementia (VaD) are intertwined by mixed dementia (MD) harboring varying degrees of AD pathology in combination with cerebrovascular disease. The aim was to assess whether there is a difference in the cerebrospinal fluid (CSF) profile, of selected proteins, between patients with VaD and MD with subcortical vascular disease (SVD), AD, and healthy controls that could contribute in the separation of the groups. The study included 30 controls, 26 SVD patients (9 VaD and 17 MD) and 30 AD patients. The protein panel included total tau (T-tau), hyperphosphorylated tau 181 (P-tau(181)), amyloid β 1-42 (Aβ(1-42)), neurofilament light (NF-L), myelin basic protein (MBP), heart fatty acid binding protein (H-FABP), matrix metalloproteinases (MMP-1, -2, -3, -9, and -10), and tissue inhibitors of metalloproteinases (TIMP-1 and -2). Immunochemical methods were utilized for quantification of the proteins in CSF and data analysis was performed with a multivariate discriminant algorithm. The concentrations of MBP, TIMP-1, P-tau(181), NF-L, T-tau, MMP-9, Aβ(1-42), and MMP-2 contributed the most to the separation between SVD and AD, with a sensitivity of 89% and a specificity of 90% (AUC = 0.92). MBP and NF-L performed the best in discriminating SVD from controls, while T-tau and Aβ(1-42) contributed the most in segregating AD from controls. The CSF biomarkers reflecting AD pathology (T-tau, P-tau(181), and Aβ(1-42)), white matter lesions (NF-L and MBP) and ma…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while increased levels of metaloproteinases MMP-1, MMP-3 and MMP-10 have also been reported in AD [223,224,225,226].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [224]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., & Perry, G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02653.1997 · Cited by 1,239 · cited 1×
“There are many detailed studies supporting these findings [68–75].”
Barrett, A. J., & Starkey, P. M. (1973) · Biochemical Journal · doi:10.1042/bj1330709 · Cited by 1,062 · cited 1×
“Further complicating the picture is the regulation of the MMPs by TIMPs and that the inhibitors have a biological function of their own [10, 11, 13, 14].”
Metalloproteinases in biology and pathology of the nervous system
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081571 · Cited by 1,060 · cited 3×
“Mounting evidence indicates that matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) may play an important role in the pathology of neurodegenerative and neuroinflammatory diseases [10–12].”
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 966
Rosenberg, G. A., Estrada, E. Y., & Dencoff, J. E. (1998) · Stroke · doi:10.1161/01.str.29.10.2189 · Cited by 861
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationHeterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations
Gouw, A. A., Seewann, A., van der Flier, W. M., Barkhof, F., Rozemuller, A. M., Scheltens, P., & Geurts, J. J. G. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204685 · Cited by 766
Progress in matrix metalloproteinase research
MURPHY, G., & NAGASE, H. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.002 · Cited by 759 · cited 2×
“structural proteins such as tight junction proteins and MBP [11, 58, 59].”
Multi- and megavariate data analysis
Eriksson, L. (2006) · Cited by 736
Cited by
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Self-citationNeurofilaments and Neurofilament Proteins in Health and Disease
Yuan, A., Rao, M. V., Veeranna, & Nixon, R. A. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018309 · Cited by 731
Human CNS barrier-forming organoids with cerebrospinal fluid production
Pellegrini, L., Bonfio, C., Chadwick, J., Begum, F., Skehel, M., & Lancaster, M. A. (2020) · Science · doi:10.1126/science.aaz5626 · Cited by 461
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
MMP‐9 in translation: from molecule to brain physiology, pathology, and therapy
Vafadari, B., Salamian, A., & Kaczmarek, L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13415 · Cited by 382
“Bjerke et al. (2011) proposed the use of MMP-9 and TIMP-1 as biomarkers of AD.”
MethodCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
“AD brains also present increased levels of other SASPs mediators: the metalloproteinases MMP1, MMP-3, and MMP-10 (Leake et al., 2000; Yoshiyama et al., 2000; Bjerke et al., 2011; Horstmann et al., 2018).”
BackgroundMatrix Metalloproteinases: A challenging paradigm of cancer management
Alaseem, A., Alhazzani, K., Dondapati, P., Alobid, S., Bishayee, A., & Rathinavelu, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.008 · Cited by 232
Consensus statement for diagnosis of subcortical small vessel disease
Rosenberg, G. A., Wallin, A., Wardlaw, J. M., Markus, H. S., Montaner, J., Wolfson, L., Iadecola, C., Zlokovic, B. V., Joutel, A., Dichgans, M., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.172 · Cited by 221
“Inflammation increases the levels of MMP-9 and MMP-3 in the CSF, while the constitutive MMP-2 that is normally present in a proform is reduced in the CSF, most likely due to activation; MMP-3 and -9 are not normally present in CSF, making them readily detectable when elevated in inflammation.(102,103,104) Matrix metal…”
BackgroundSelf-citationBrkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
“proposed MMP-9 and TIMP-1 as biomarkers of AD, next to T-tau, P-tau, Aβ 1–42, and white matter lesions [52].”
BackgroundDu, S.-Q., Wang, X.-R., Xiao, L.-Y., Tu, J.-F., Zhu, W., He, T., & Liu, C.-Z. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9915-1 · Cited by 203
Tian, Z., Ji, X., & Liu, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116224 · Cited by 195
“Increased levels of matrix metalloproteinase (MMP) family inflammatory mediators were also detected in the cerebrospinal fluid of VCID patients [115].”
BackgroundBehl, T., Kaur, G., Sehgal, A., Bhardwaj, S., Singh, S., Buhas, C., Judea-Pusta, C., Uivarosan, D., Munteanu, M. A., & Bungau, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031413 · Cited by 186
Extracellular matrix inflammation in vascular cognitive impairment and dementia
Rosenberg, G. A. (2017) · Clinical Science · doi:10.1042/cs20160604 · Cited by 185
Molecular biomarkers for vascular cognitive impairment and dementia
Hosoki, S., Hansra, G. K., Jayasena, T., Poljak, A., Mather, K. A., Catts, V. S., Rust, R., Sagare, A. P., Kovacic, J. C., Brodtmann, A. G., et al. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00884-1 · Cited by 185
“In a comparison of people with SIVD or AD and healthy controls, CSF levels of MMP-3 did not differ significantly 78,84 .”
BackgroundResultInfluentialSelf-citationReduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., Wallin, A., Bjerke, M., Zetterberg, H., Blennow, K., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000437306.37850.22 · Cited by 156
“All patients underwent detailed clinical examination as described previously.(6) Samples from both cohorts were collected and treated in an identical manner according to standard operating procedures.”
MethodSelf-citationPathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 183
Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L.-O., SarrÃa, A., & Serrano-Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 142
“The biomarkers contributing the most to the discrimination between AD and controls were in the following order: Aβ42, T-tau, NF-L (neurofilament light), MMP-10 (myelin basic protein), p-tau-181, H-FABP (heart fatty acid binding protein), and MBP (matrix metalloproteinases). eHulstaert’s index: Aβ42/[p-tau(3.694+0.0105…”
BackgroundMethodInfluentialChiasserini, D., Biscetti, L., Eusebi, P., Salvadori, N., Frattini, G., Simoni, S., De Roeck, N., Tambasco, N., Stoops, E., Vanderstichele, H., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0276-4 · Cited by 134
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170680 · Cited by 132
“The A 1–42/A 1–40 ratio is decreased in AD and more accurately differentiates between AD and controls, FTLD, VaD, and DLB, due to the latter four groups having ratios that approach control levels because of decreased concentrations in both A 1–42 and A 1–40.”
BackgroundSelf-citationUpdate on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease
Wallin, A., Román, G. C., Esiri, M. M., Kettunen, P., Svensson, J., Paraskevas, G. P., & Kapaki, E. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170803 · Cited by 141
Self-citationThe choroid plexus-cerebrospinal fluid interface in Alzheimer′s disease: more than just a barrier
Vandenbroucke, R., Balusu, S., Brkic, M., & Libert, C. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.180372 · Cited by 118
“So far, there are no clear data from humans about the role of MMPs in BCSFB breakdown in AD, although several authors reported increased presence of specific MMPs in CSF, plasma and serum of AD patients (Horstmann et al., 2010; Bjerke et al., 2011).”
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Mallick, R., Basak, S., & Duttaroy, A. K. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101116 · Cited by 134
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 114
“In case of doubt between VaD or mixed AD–CVD pathology in dementia patients, the determination of CSF Ab1-42, T-tau, and P-tau181 levels is of help to confirm or exclude the AD component in the pathophysiology of the dementia syndrome [58].”
Self-citationLlorens, F., Hermann, P., Villar-Piqué, A., Diaz-Lucena, D., Nägga, K., Hansson, O., Santana, I., Schmitz, M., Schmidt, C., Varges, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14373-2 · Cited by 114
Self-citationRivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
“It has been proposed that the concentration of TIMP-1 in the CSF is a distinctive biomarker to differentiate AD patients from those with subcortical vascular disease, the latter having higher levels than the former [107].”
BackgroundJin, M., Cao, L., & Dai, Y.-P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00254 · Cited by 102
Zhao, Y., Xin, Y., Meng, S., He, Z., & Hu, W. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.014 · Cited by 105
Monocyte and microglial activation in patients with mood-stabilized bipolar disorder
Jakobsson, J., Bjerke, M., Sahebi, S., Isgren, A., Ekman, C. J., Sellgren, C., Olsson, B., Zetterberg, H., Blennow, K., Pålsson, E., et al. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140183 · Cited by 101
“79§ Duration of illness, yr† — 12e [4–19] — — 10f [4–19] — Age at onset, yr† — 23e [18–32] — — 23f [18–32] — No.”
Self-citationCipollini, V., Troili, F., & Giubilei, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112812 · Cited by 98
“Some studies have demonstrated that the evaluation of MMPs in CSF have high validity in discriminating VCID from cognitive impairment of primarily neurodegenerative etiology [12,101,102].”
BackgroundRosenberg, G. A., Bjerke, M., & Wallin, A. (2014) · Stroke · doi:10.1161/strokeaha.113.004534 · Cited by 97
Self-citationNyúl‐Tóth, Á., Patai, R., Csiszár, A., Ungvari, A., Gulej, R., Mukli, P., Yabluchanskiy, A., Benyó, Z., Sótonyi, P., Prodan, C. I., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01194-0 · Cited by 101
“Examples include CSF/plasma albumin ratio [117, 118], CSF fibrinogen levels [129], levels of matrix metallopeptidases 2 and 9 (MMP2 and MMP9) in serum and CSF [130–132], and soluble platelet-derived growth factor receptor beta (sPDGFRβ) content in CSF [133–135].”
BackgroundNeuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke
Hjalmarsson, C., Bjerke, M., Andersson, B., Blennow, K., Zetterberg, H., Åberg, N. D., Olsson, B., Eckerström, C., Bokemark, L., & Wallin, A. (2014) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s13821 · Cited by 94
Self-citationNew fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
Park, S. A., Han, S. M., & Kim, C. E. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0418-9 · Cited by 91
Jakobsson, J., Bjerke, M., Ekman, C. J., Sellgren, C. M., Johansson, A. G. M., Zetterberg, H., Blennow, K., & Landén, M. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.81 · Cited by 97
“Products found in CSF are thought to reflect some aspects of brain biochemistry and markers of brain injury may thus be established (Bjerke et al, 2011).”
BackgroundSelf-citationMatrix metalloproteinases in Alzheimer’s disease and concurrent cerebral microbleeds.
Duits, F. H., Hernandez-Guillamon, M., Montaner, J., Goos, J. D. C., Montañola, A., Wattjes, M. P., Barkhof, F., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143186 · Cited by 92
“Our findings may partly explain the inconsistency of previous findings on MMPs in as well AD patients as VaD patients as both patient groups could have consisted partly of patients with concurrent CAA pathology, possibly confounding the results [21, 22, 24, 26].”
InfluentialWallin, A., Kapaki, E., Boban, M., Engelborghs, S., Hermann, D. M., Huisa, B., Jonsson, M., Kramberger, M. G., Lossi, L., Malojcic, B., et al. (2017) · BMC Neurology · doi:10.1186/s12883-017-0877-3 · Cited by 89
“Reduction of CSF Aβ42 in VCI of any type [106] and VCI-SSVD with or without signs of AD [33, 72, 108, 109], at levels similar to AD or intermediate between controls and AD have been reported.”
BackgroundResultInfluentialSelf-citationUpdate on the Neurobiology of Vascular Cognitive Impairment: From Lab to Clinic
Vinciguerra, L., Lanza, G., Puglisi, V., Fisicaro, F., Pennisi, M., Bella, R., & Cantone, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082977 · Cited by 74
“Additionally, the increase of selected protein panel, such as Aβ1-42, T-tau, P-tau, myelin basic protein, tissue inhibitors of metalloproteinases-1 (TIMP-1), NF-L, matrix metalloproteinases (MMP)-9, and MMP-2, was found to be helpful in differentiating SIVD patients with cognitive decline from AD, with a sensitivity o…”
BackgroundShi, M., Movius, J., Dator, R., Aro, P., Zhao, Y., Pan, C., Lin, X., Bammler, T. K., Stewart, T., Zabetian, C. P., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.040576 · Cited by 70
“tected in human CSF (48, 49) and our finding of lower TIMP1”
BackgroundBlood-based biomarkers of cerebral small vessel disease
Wu, L., Chai, Y. L., Cheah, I. K.-M., Chia, R. S. L., Hilal, S., Arumugam, T. V., Chen, C., & Lai, M. K. P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102247 · Cited by 73
“While measurements of MMPs in the CSF have been found to have high ability in discriminating VCI from AD and controls (Bjerke et al., 2011, Candelario-Jalil et al., 2011), the potential clinical utility of peripheral MMPs for the identification and staging of CSVD require further assessments.”
BackgroundResultInfluentialHanzel, C. E., Iulita, M. F., Eyjolfsdottir, H., Hjorth, E., Schultzberg, M., Eriksdotter, M., & Cuello, A. C. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132282 · Cited by 64
“Interestingly, recent studies showed that certain MMPs, in combination with the AD biomarkers A and tau, are relevant for discrimination between vascular dementia and AD given their role in bloodbrain barrier permeability [7].”
BackgroundPaoletti, F. P., Simoni, S., Parnetti, L., & Gaetani, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094958 · Cited by 80
Mroczko, B., Groblewska, M., & Barcikowska, M. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130647 · Cited by 61
“CSF levels of TIMP-1 and TIMP-2 in Inspector et controls Plasma TIMP-1 Bjerke et al., 2011 AD, VaD, SVD, healthy CSF levels of MMP-1, MMP-2, MMP-3, decreased levels of TIMP-1 levels of MMP-9 and TIMP-1 in AD lower than in SVD in healthy controls MMP-2 and TIMP-1contributed to differentiate between AD and profiles diffe…”
InfluentialWu, D., Tang, X., Gu, L., Li, X., Qi, X., Bai, F., Chen, X., Wang, J., Ren, Q., & Zhang, Z. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12809 · Cited by 64
BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASE
Rosenberg, G. A. (2014) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.25 · Cited by 62
“These studies in animals are mirrowed in human studies showing that MMP-9, which disrupts the BBB by attacking basal lamina and the tight junction proteins, is elevated in patients with SIVD, but not AD (24, 25).”
BackgroundCSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment
Rolstad, S., Jakobsson, J., Sellgren, C. M., Isgren, A., Ekman, C. J., Bjerke, M., Blennow, K., Zetterberg, H., Pålsson, E., & Landén, M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.023 · Cited by 67
“Interestingly, mounting evidence suggests an association between neuroinflammation and cognitive dysfunction (Bjerke et al., 2011).”
Self-citationGuo, L., Alexopoulos, P., & Perneczky, R. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0405-4 · Cited by 64
“Several recent works using conventional ELISA methods have demonstrated increased hFABP CSF concentrations in patients with AD dementia [2, 10, 46].”
Vilar‐Bergua, A., Llena, I. R., Nafría, C., Bustamante, A., Llombart, V., Delgado, P., & Montaner, J. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.68 · Cited by 64
“Moreover, all of them together plus MMP2, MMP-9, and tissue inhibitor of metalloproteinase-1 are able to distinguish between AD and SIVD with elevated sensitivity and specificity.(98) Likewise, another study performed in two independent cohorts determined a panel of 90 CSF proteins in several types of clinically estab…”
ResultKhan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 67
“Using multivariate analysis and a combination of CSF total tau, p-tau, A 1-42, matrix metalloproteinases, and tissue inhibitors of metalloproteinasescan separate AD from SVaD with high sensitivity, specificity, and accuracy [53].”
MethodCSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
van der Ende, E. L., Veld, S. G. J. G. I. ‘., Hanskamp, I., van der Lee, S. J., Dijkstra, J. I. R., Hok‐A‐Hin, Y. S., Blujdea, E. R., Swieten, J. C. V., Irwin, D. J., Chen‐Plotkin, A. S., et al. (2023) · Brain · doi:10.1093/brain/awad213 · Cited by 62
The Role of Glial Cell Senescence in Alzheimer's Disease
Alshaebi, F., Sciortino, A., & Kayed, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70051 · Cited by 60
Maher‐Edwards, G., De'Ath, J., Barnett, C., Lavrov, A., & Lockhart, A. (2015) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.003 · Cited by 54
“NF-L was assessed as an exploratory measure of white matter (axonal) damage, as it has been reported to be increased in some forms of dementia with subcortical involvement [28] and in demyelinating diseases, such as multiple sclerosis where treatmentrelated reductions in this marker have been noted [29].”
BackgroundMroczko, B., Groblewska, M., Zboch, M., Kulczyńska, A., Koper, O. M., Szmitkowski, M., Kornhuber, J., & Lewczuk, P. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131634 · Cited by 57
“[8] found that the CSF concentrations of MMP-9 and TIMP-1 were elevated in the group of patients with AD and concomitant cerebrovascular dementia, but not in “pure” AD.”
BackgroundBiofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias
Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 59
“A CSF pattern consisting of elevated NfL and matrix metalloproteinases, in combination with decreased soluble APP has emerged 141,142 .”
Self-citationMatrix Metalloproteinases and Their Multiple Roles in Alzheimer's Disease
Wang, X.-X., Tan, M.-S., Yu, J.-T., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/908636 · Cited by 55
“Moreover, low-density receptor-related protein can act as a receptor for MMP-9, which mediates internalization and degradation of the enzyme [19].”
Wu, C.-Y., Bawa, K. K., Ouk, M., Leung, N., Yu, D., Lanctôt, K. L., Herrmann, N., Pakosh, M., & Swardfager, W. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101130 · Cited by 51
The Link Between Matrix Metalloproteinases and Alzheimer’s Disease Pathophysiology
Radošinská, D., & Radošinská, J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04315-0 · Cited by 56
Perivascular space dysfunction in cerebral small vessel disease is related to neuroinflammation
Hong, H., Tozer, D. J., Chen, Y., Brown, R. B., Low, A., & Markus, H. S. (2024) · Brain · doi:10.1093/brain/awae357 · Cited by 54
“…with BBB leakage at some time, and an increased CSF-to-serum albumin ratio, a marker of increased BBB permeability, has been reported in cSVD. 23,24 Increased BBB permeability can be measured non-invasively, using dynamic contrast-enhanced MRI (DCE-MRI) to measure the T 1 relaxation time…”
Biomarkers Assessing Endothelial Dysfunction in Alzheimer’s Disease
Custodia, A., Aramburu-Núñez, M., Rodríguez-Arrizabalaga, M., Pías-Peleteiro, J. M., Vázquez-Vázquez, L., Camino-Castiñeiras, J., Aldrey, J. M., Castillo, J., Ouro, A., Sobrino, T., et al. (2023) · Cells · doi:10.3390/cells12060962 · Cited by 44
“[98] - CSF samples from AD patients displayed increased levels of MMP-10, which were correlated with T-tau concentration.”
BackgroundBai, Z., Stamova, B., Xu, H., Ander, B. P., Wang, J., Jickling, G. C., Zhan, X., Liu, D., Han, G., Jin, L.-W., et al. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000022 · Cited by 52
Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization
Cheng, A., Shinoda, Y., Yamamoto, T., Miyachi, H., & Fukunaga, K. (2019) · Brain Research · doi:10.1016/j.brainres.2018.11.036 · Cited by 50
Skillbäck, T., Zetterberg, H., Blennow, K., & Mattsson, N. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt212 · Cited by 48
“NFL is often normal in clinically pure AD [19] but abnormal in the presence of vascular pathology (for example, small-vessel disease [20], which mainly affects subcortical brain regions).”
BackgroundMethodSelf-citationThe Role of Oxidative Stress and Inflammation in the Pathogenesis and Treatment of Vascular Dementia
Altahrawi, A. Y., James, A. W., & Shah, Z. A. (2025) · Cells · doi:10.3390/cells14080609 · Cited by 53
Wallin, A., Nordlund, A., Jonsson, M., Blennow, K., Zetterberg, H., Öhrfelt, A., Stålhammar, J., Eckerström, M., Carlsson, M., Olsson, E., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.148 · Cited by 48
Self-citationMatrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer’s type
Martino Adami, P. V., Orellana, A., García, P., Kleineidam, L., Alarcón-Martín, E., Montrreal, L., Aguilera, N., Espinosa, A., Abdelnour, C., Rosende-Roca, M., et al. (2022) · Brain · doi:10.1093/brain/awac024 · Cited by 46
Sulfur-containing therapeutics in the treatment of Alzheimer’s disease
Zhu, H., Dronamraju, V., Xie, W., & More, S. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02687-1 · Cited by 48
Olsson, B., Hertze, J., Ohlsson, M., Nägga, K., Höglund, K., Basun, H., Annas, P., Lannfelt, L., Andreasen, N., Minthon, L., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121384 · Cited by 46
“Besides AD, HFABP have also been shown to be elevated in Creutzfeldt-Jakob disease, Lewy body dementia, Parkinson’s disease [28], and VaD [14, 15], indicating that on its own it is not a disease-specific biomarker for AD but rather a general marker of neurodegeneration.”
Self-citationExplorative and targeted neuroproteomics in Alzheimer's disease
Brinkmalm, A., Portelius, E., Öhrfelt, A., Brinkmalm, G., Andréasson, U., Gobom, J., Blennow, K., & Zetterberg, H. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.01.009 · Cited by 47
Self-citationDiagnostic challenges in rapidly progressive dementia
Zerr, I., & Hermann, P. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1519397 · Cited by 46
“Neurofilament light [76,77] and matrix metalloproteinases [78] have also been identi-”
BackgroundLiu, K., Li, W., Pan, R., & Qi, Z. (2018) · Brain Circulation · doi:10.4103/bc.bc_11_18 · Cited by 42
Boström, G., Freyhult, E., Virhammar, J., Alcolea, D. A., Tumani, H., Otto, M., Brundin, R., Kilander, L., Löwenmark, M., Giedraitis, V., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201565 · Cited by 43
“Previously, a combination of eight proteins, including TIMP-1, MMP-9, and MMP-2, but not MMP-10, was shown to discriminate patients with subcortical vascular disease from patients with AD, with a sensitivity of 89% and a specificity of 90% [29].”
Biomarkers in Alzheimer’s disease
Janeiro, M. H., Ardanaz, C. G., Sola-Sevilla, N., Dong, J., Cortés-Erice, M., Solas, M., Puerta, E., & Ramírez, M. J. (2020) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0090 · Cited by 49
“High level of NFL may reflect ongoing damage and demyelination [9].”
BackgroundCellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 43
Kaminari, A., Tsilibary, E. C., & Tzinia, A. K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180035 · Cited by 42
Rosenberg, G. A., Prestopnik, J., Adair, J. C., Huisa, B. N., Knoefel, J. E., Caprihan, A., Gasparovic, C., Thompson, J. F., Erhardt, E. B., & Schrader, R. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309421 · Cited by 42
Tofiq, A., Zetterberg, H., Blennow, K., Basun, H., Cederholm, T., Eriksdotter, M., Irving, G. F., Hjorth, E., Jernerén, F., Schultzberg, M., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210007 · Cited by 39
“More recently, neurofilament light (NfL), a protein indicating axonal damage in the white matter of the brain, was found to be elevated in AD as compared to healthy controls [4,26].”
Self-citationRole of FABP3 as Biomarker in Alzheimer's Disease and Synucleinopathies
Sepe, F. N., Chiasserini, D., & Parnetti, L. (2018) · Future Neurology · doi:10.2217/fnl-2018-0003 · Cited by 38
Perneczky, R., Tene, O., Attems, J., Giannakopoulos, P., Ikram, M. A., Federico, A., Sarazin, M., & Middleton, L. T. (2016) · BMC Medicine · doi:10.1186/s12916-016-0719-y · Cited by 42
“Some biomarker candidates, such as matrix metalloproteinases [26], have been proposed, but the evidence thus far remains unconvincing.”
BackgroundBrown, R. B., Tozer, D. J., Loubière, L. S., Harshfield, E. L., Hong, Y. T., Fryer, T. D., Williams, G. B., Graves, M. J., Aigbirhio, F. I., O'Brien, J. T., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13830 · Cited by 36
“MMP-9 is associated with ECM remodeling and discriminates well between patients with vascularcognitiveimpairmentandAlzheimer’sdisease, 5 butitispossi-blethatmeasurementintheserumisnotsensitiveenoughtocapturea treatment effect.”
BackgroundMatrix metalloproteinase levels in early HIV infection and relation to in vivo brain status
Li, S., Wu, Y. G., Keating, S. M., Du, H., Sammet, C. L., Zadikoff, C., Mahadevia, R. J., Epstein, L. G., & Ragin, A. B. (2013) · Journal of NeuroVirology · doi:10.1007/s13365-013-0197-3 · Cited by 36
“CSFMMP-9 levels in the Chicago Early HIV cohort were generally higher than levels reported for controls in other studies; results reported for CSF MMP-2 levels in controls, however, were widely variable across different studies (Bjerke et al. 2011; Leppert et al. 1998; Niebroj-Dobosz et al. 2010; Yushchenko et al. 200…”
Baidya, S. K., Banerjee, S., Adhikari, N., & Jha, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01855 · Cited by 36
Ioannou, P., Katsoulieris, E. N., & Afratis, N. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083621 · Cited by 36
Diagnosis of vascular cognitive impairment and its main categories
García, P. L. R., & García, D. R. (2015) · Neurología (English Edition) · doi:10.1016/j.nrleng.2011.12.013 · Cited by 40
“Nevertheless, using CSF biomarkers to diagnose vascular dementia requires a standardised procedure for obtaining, storing, and measuring the samples.(5,95,96,105)”
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Diagnóstico del deterioro cognitivo vascular y sus principales categorías
Rodríguez García, P. L., & Rodríguez García, D. (2015) · Neurología · doi:10.1016/j.nrl.2011.12.014 · Cited by 33
Minta, K., Brinkmalm, G., Portelius, E., Johansson, P., Svensson, J., Kettunen, P., Wallin, A., Zetterberg, H., Blennow, K., & Andréasson, U. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201039 · Cited by 34
“For instance, CSF MMP-9, but not MMP-2, -3, -10, concentrations were previously observed to be increased in VaD compared to AD patients [40, 41].”
Self-citationBjerke, M., Jonsson, M. A. G., Nordlund, A., Eckerström, C., Blennow, K., Zetterberg, H., Pantoni, L., Inzitari, D., Schmidt, R., & Wallin, A. (2014) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000366119 · Cited by 32
Self-citationMeulenbroek, O., O'Dwyer, S., de Jong, D., van Spijker, G. J., Kennelly, S., Cregg, F., Rikkert, M. G. M. O., Abdullah, L. I., Wallin, A., Walsh, C., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011584 · Cited by 32
Self-citationKim, Y., Kim, Y., Kim, N. K., Kim, S.-H., Kim, O. J., & Oh, S. (2014) · European Neurology · doi:10.1159/000362876 · Cited by 32
Králová, K., Fousková, M., Habartová, L., Fišar, Z., Jirák, R., Raboch, J., & Setnička, V. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.002 · Cited by 33
Dulewicz, M., Kulczyńska‐Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143009 · Cited by 32
Trentini, A., Manfrinato, M. C., Castellazzi, M., & Bellini, T. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081196 · Cited by 32
Ge, J., Li, R., Yuan, P., Che, B., Bu, X., Shao, H., Xu, T., Ju, Z., Zhang, J., Zhang, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15369 · Cited by 30
Metalloproteinases and their inhibitors in neurological disease
Lopez-Navarro, E. R., & Gutierrez, J. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02188-x · Cited by 28
“TIMP-1 and MMP-9 have been proposed as CSF-markers, in addition to T-Tau, P-Tau181, and Aβ1-42 (Bjerke et al. 2011).”
BackgroundInfluentialCirillo, G., Colangelo, A. M., De Luca, C., Savarese, L., Barillari, M. R., Alberghina, L., & Papa, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152750 · Cited by 27
“MMP-2 and MMP-9 are also increased in Alzheimer’s disease (AD) patients [18] and in neural progenitor cells (NPC) of subventricular and subgranular zone of the dentate gyrus in brain ischemic animal models [19].”
BackgroundThe possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts
Al-Kuraishy, H. M., Al-Gareeb, A. I., Zekry, S. H., Alruwaili, M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.01.040 · Cited by 28
“Moreover, neuroinflammation mediators such as TNF-α 1 and IL-1 β are increased in vascular cognitive impairment and VD in both animals and humans (Bjerke et al., 2011; Fu et al., 2014).”
Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease
Wallin, A., Öhrfelt, A., & Bjerke, M. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.068 · Cited by 29
“The main findings contributing to the multivariate separation representing a subcortical profile were the markers MBP, TIMP-1, NFL and MMP-9, while the cortical profile mainly consisted of T-tau, P-tau and Aβ1–42 [39].”
BackgroundSelf-citationRosenberg, G. A. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0277-4 · Cited by 28
“In one study, there was a increase in TIMP-1 in CSF in VCI (Bjerke et al. 2011).”
Biomarcadores en la enfermedad de Alzheimer
Janeiro, M. H., Ardanaz, C. G., Sola-Sevilla, N., Dong, J., Cortés-Erice, M., Solas, M., Puerta, E., & Ramírez, M. J. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0109 · Cited by 33
“Niveles elevados de NFL pueden ser indicativos de que se está produciendo daño axonal y desmielinización [9].”
Background
Metadata
- Authors
- Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U.
- Affiliations
- University of Gothenburg (SE)
- Institute of Neuroscience and physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
- Corresponding author
- Bjerke, Maria
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-11-29
- Volume
- 27
- Issue
- 3
- Pages
- 665-676
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1585099387
- Cited by
- 180
- References
- 78
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 18 · 2022: 14 · 2021: 16 · 2020: 17 · 2019: 12 · 2018: 12 · 2017: 14 · 2016: 10 · 2015: 19 · 2014: 13 · 2013: 11 · 2012: 3
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- vascular dementia, Alzheimer's disease
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Myelin Basic Protein, Female, Humans, Male, Middle Aged, Phosphorylation, Dementia, Vascular, Biomarkers, tau Proteins, Neurofilament Proteins, Tissue Inhibitor of Metalloproteinase-1, Matrix Metalloproteinase 9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.